Hyung J Chun

Summary

Affiliation: Yale University
Country: USA

Publications

  1. Hwangbo C, Lee H, Kang H, Ju H, Wiley D, Papangeli I, et al. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension. Circulation. 2017;135:2288-2298 pubmed publisher
    ..Our findings identify VEGFR3 as a key regulator of endothelial BMPR2 signaling and a potential determinant of PAH penetrance in humans. ..
  2. Kim J, Hwangbo C, Hu X, Kang Y, Papangeli I, Mehrotra D, et al. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation. 2015;131:190-9 pubmed publisher
    ..Moreover, we identify selective HDAC IIa inhibition as a viable alternative approach to avoid the potential adverse effects of broad spectrum HDAC inhibition in PAH. ..
  3. Lee A, Papangeli I, Park Y, Jeong H, Choi J, Kang H, et al. A PPARγ-dependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. Sci Rep. 2017;7:2528 pubmed publisher
    ..Overall, these studies identify a PPARγ-dependent miR-424/503-CD40 signaling axis that is critical for regulation of inflammation mediated angiogenesis. ..
  4. Hwangbo C, Wu J, Papangeli I, Adachi T, Sharma B, Park S, et al. Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects. Sci Transl Med. 2017;9: pubmed publisher
    ..Treatment of these mice with an FABP4 inhibitor abrogated these metabolic phenotypes. These findings provide mechanistic insights that could greatly expand the therapeutic repertoire for type 2 diabetes and related metabolic disorders. ..
  5. Papangeli I, Chun H. A Tale of Two Elabela Null Mice. Trends Endocrinol Metab. 2017;28:759-760 pubmed publisher
    ..Two new studies report on the phenotypes of Ela null mice, ranging from defective embryogenesis to preeclampsia, providing new insights and raising greater intrigue on this cardiometabolic pathway. ..